Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 9.7% - Time to Sell?

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report)'s stock price traded down 9.7% during mid-day trading on Friday . The stock traded as low as $11.65 and last traded at $11.51. 377,743 shares traded hands during trading, a decline of 56% from the average session volume of 857,345 shares. The stock had previously closed at $12.74.

Analysts Set New Price Targets

Several research analysts have recently issued reports on the company. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital began coverage on Stoke Therapeutics in a research report on Friday, December 20th. They set a "buy" rating and a $24.00 price objective for the company. Leerink Partners began coverage on Stoke Therapeutics in a research report on Monday, October 14th. They issued an "outperform" rating and a $18.00 target price for the company. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, January 8th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $21.29.

Stoke Therapeutics Stock Performance

The firm has a fifty day moving average price of $11.06 and a 200 day moving average price of $12.56. The firm has a market capitalization of $546.65 million, a price-to-earnings ratio of -4.91 and a beta of 0.95.

Insider Activity

In related news, General Counsel Jonathan Allan sold 9,696 shares of Stoke Therapeutics stock in a transaction on Friday, December 6th. The stock was sold at an average price of $12.78, for a total transaction of $123,914.88. Following the completion of the transaction, the general counsel now directly owns 35,142 shares of the company's stock, valued at approximately $449,114.76. The trade was a 21.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Barry Ticho sold 10,000 shares of Stoke Therapeutics stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $12.07, for a total value of $120,700.00. Following the transaction, the insider now directly owns 51,277 shares of the company's stock, valued at approximately $618,913.39. This represents a 16.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock valued at $809,421 in the last three months. 11.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. RTW Investments LP raised its holdings in Stoke Therapeutics by 10.1% during the third quarter. RTW Investments LP now owns 4,652,285 shares of the company's stock worth $57,177,000 after purchasing an additional 427,447 shares during the last quarter. State Street Corp raised its holdings in shares of Stoke Therapeutics by 8.6% in the third quarter. State Street Corp now owns 1,728,888 shares of the company's stock worth $21,248,000 after acquiring an additional 137,145 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Stoke Therapeutics by 2.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company's stock worth $14,901,000 after acquiring an additional 38,446 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Stoke Therapeutics by 9.7% in the third quarter. Geode Capital Management LLC now owns 870,831 shares of the company's stock worth $10,705,000 after acquiring an additional 76,661 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Stoke Therapeutics by 8.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 342,129 shares of the company's stock worth $3,774,000 after acquiring an additional 25,995 shares during the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.